Oncogenic mutations in the splicing factor SRSF2 activate a mitochondrial surveillance mechanism, providing a therapeutic vulnerability in SRSF2-mutant acute myeloid leukemia and myelodysplastic syndrome. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.